Todays City Moves includes Circassia, Bank of America Merrill Lynch and RPMI.
Dr Rod Hafner, senior vice president of research and development at Circassia Pharmaceuticals, a specialty biopharmaceutical company focused on respiratory disease, will step down from the board after 11 years as a director. However, Rod will remain part of the senior management team and will continue in his role leading its business development, supply chain, medical affairs, regulatory and quality activities. Meanwhile, Jonathan Emms has been appointed to the newly-created role of chief operating officer (COO). Prior to joining, Jonathan was chief commercial officer for Pfizers internal medicines organisation, where he led commercial activities across the companys global operations. Previously, he held a number of senior posts at Pfizer, and oversaw the UK launch of Spiriva under the companys co-promotion agreement with Boehringer Ingelheim.
Bank of America Merrill Lynch
Bank of America Merrill Lynch (BofAML) has appointed Gerardus Vos as head of financial technology investment banking for Europe, Middle East and Africa (EMEA). He will join the firm in September, and be based in London. Gerardus joins from Barclays where he was head of technology and fintech equities research. He has 19 years of experience, primarily at Barclays and Citi covering the technology, software and payments sectors as a consistently top ranked analyst. In this newly created role, Gerardus will be based within BofAMLs EMEA financial institutions group and report to Giorgio Cocini and Arif Vohra, co-heads of EMEA financial institutions investment banking. He will partner closely with colleagues across the financial institutions team in EMEA and globally, as well as our country team colleagues, to drive strategic dialogue with companies in the payments and financial technology sectors as well as in the broader financial services sector. The bank acted as sole financial adviser to Mastercard in the €2.85bn (£2.64bn) acqRead More – Source